Search Results

You are looking at 71 - 80 of 177 items for :

  • "cetuximab" x
  • All content x
Clear All
Full access

Charu Aggarwal, Neeta Somaiah, and George R. Simon

association of KRAS mutations and response to cetuximab seems to be less clear in NSCLC and contrary to the experience in colon cancer. Tumor samples from the FLEX study, a study that compared the triplet combination of cisplatin/vinorelbine/cetuximab with a

Full access

Michael S. Lee, David G. Menter, and Scott Kopetz

among patients with KRAS wild-type, refractory, metastatic CRC. In the CO.17 randomized trial, among those with KRAS codon 12/13 wild-type disease, there was a significant improvement in PFS with cetuximab in patients with a left-sided primary (HR, 0

Full access

Erich M. Sturgis and K. Kian Ang

locally advanced cancers are radiation with concurrent cisplatin 47 or cetuximab, 48 induction chemotherapy followed by radiation with or without concurrent systemic therapy, 49 , 50 and surgery with postoperative radiation with or without concurrent

Full access

Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson III, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Anne Covey, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman Jr., Charles Fuchs, Jean L. Grem, Krystyna Kiel, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Sujata Rao, David P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, Constantinos Sofocleous, James Thomas, Alan P. Venook, and Christopher Willett

predict disease control in metastatic colorectal cancer patients treated with cetuximab . J Clin Oncol 2007 ; 25 : 3230 – 3237 . 33 De Roock W Piessevaux H De Schutter J . KRAS wild-type state predicts survival and is associated to early

Full access

Margaret Tempero

Outcomes at MSKCC (who co-wrote with Dr. Saltz about the efforts with ziv-aflibercept). Dr. Bach proposed this in an article published in JAMA last year, 3 in which he used the example of variable pricing for cetuximab, proposing a near 20-fold variation

Full access

following regimens were added for chordoma: Imatinib with cisplatin or sirolimus Erlotinib + cetuximab Sunitinib Ewing's Sarcoma: Under “Primary therapy for metastatic disease at initial presentation,” included the

Full access

Angela Jain, Paula D. Ryan, and Michael V. Seiden

(FOLFIRI) and cetuximab was initiated but discontinued secondary to a hypersensitivity reaction with the first cycle. Single-agent trastuzumab was started, and over 3 weekly doses the patient’s CEA trended from 499 to 871, then 664. Restaging CT scan at

Full access

Chloe E. Atreya, Claire Greene, Ryan M. McWhirter, Nabia S. Ikram, I. Elaine Allen, Katherine Van Loon, Alan P. Venook, Benjamin M. Yeh, and Spencer C. Behr

. 16. Bokemeyer C Van Cutsem E Rougier P . Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials . Eur J Cancer 2012 ; 48

Full access

David G. Pfister, Sharon Spencer, David M. Brizel, Barbara Burtness, Paul M. Busse, Jimmy J. Caudell, Anthony J. Cmelak, A. Dimitrios Colevas, Frank Dunphy, David W. Eisele, Jill Gilbert, Maura L. Gillison, Robert I. Haddad, Bruce H. Haughey, Wesley L. Hicks Jr, Ying J. Hitchcock, Antonio Jimeno, Merrill S. Kies, William M. Lydiatt, Ellie Maghami, Renato Martins, Thomas McCaffrey, Loren K. Mell, Bharat B. Mittal, Harlan A. Pinto, John A. Ridge, Cristina P. Rodriguez, Sandeep Samant, David E. Schuller, Jatin P. Shah, Randal S. Weber, Gregory T. Wolf, Frank Worden, Sue S. Yom, Nicole R. McMillian, and Miranda Hughes

disease is concurrent systemic therapy and RT (with high-dose cisplatin as the preferred [category 1] systemic agent). 222 Other category 1 systemic therapy/RT options include carboplatin/5-FU or (2) cetuximab. 102 , 223 Other recommended systemic

Full access

Amy Zhou, Manik Amin, Kathryn J. Fowler, Elizabeth M. Brunt, Jesse Keller, and Benjamin Tan

demonstrated no difference in median progression-free survival (PFS) or OS between the cohorts. 34 A similar study was conducted using another EGFR inhibitor, cetuximab, which also failed to demonstrate an improvement in PFS or OS. 35 The significance of the